Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

News in Brief

India Adds Compulsory Drug Licenses

DOI: 10.1158/2159-8290.CD-NB2013-016 Published March 2013
  • Article
  • Info & Metrics
Loading

The Indian government is aggressively regulating the price of widely used cancer drugs—a measure that may help some patients and the country's domestic drug industry in the short term but may end up denying those with rare conditions access to life-saving medications, economists say.

In mid-January, the government granted compulsory licenses for 3 cancer drugs, including the breast cancer agents Herceptin (trastuzumab; Genentech/Roche) and Ixempra (ixabepilone; Bristol-Myers Squibb) and the leukemia therapeutic Sprycel (dasatinib; Bristol-Myers Squibb). The licenses allow Indian companies to make and sell generic versions of the drugs below the market rate.

“Sprycel and Ixempra are protected by patents granted by the Indian Patent Office,” responds a Bristol-Meyers Squibb spokesperson. “Bristol-Myers Squibb has and will continue to pursue all appropriate avenues to protect its intellectual property rights in India.”

Roche “has taken steps to increase access to a number of our drugs in India, including Herceptin,” comments a spokesperson. Last year, Roche reportedly cut the cost of Herceptin and MabThera (rituximab) in India, renaming them for the local market and packaging them there.

Compulsory licenses and other efforts to rein in medication costs are good for generic manufacturers in India and for middle-class patients, who will now be able to afford a drug they might not have been able to afford otherwise, says Ernst R. Berndt, PhD, a professor of applied economics at Massachusetts Institute of Technology's Sloan School of Management in Cambridge.

But as India gets wealthier, “I think it's going to be more and more of a problem,” he says. “A lot of Western companies have not attempted to sell their drugs in India knowing it would likely be genericized.”

As a result, drugs that are aimed at a smaller market than blockbusters like Herceptin do not reach the country at all, says Berndt.

Roger Bate, PhD, a resident scholar at the American Enterprise Institute in Washington, DC, is more critical of the Indian government, pointing out that in addition to compulsory licenses for patented drugs, the government has denied patent approvals for Bayer, Gilead, Novartis, Pfizer, and Roche products that are now in litigation. The government's policies, he says, are “creating antagonism and lowering foreign investment.”

Bate suggests that the Indian government should do more to clarify its regulations and that focusing solely on the price of drugs will drive production costs too low, sacrificing drug safety. Even artificially low prices are too expensive for many people in India, where the per capita annual income is about $1,000.

  • ©2013 American Association for Cancer Research.
View Abstract
PreviousNext
Back to top
Cancer Discovery: 3 (3)
March 2013
Volume 3, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
India Adds Compulsory Drug Licenses
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
India Adds Compulsory Drug Licenses
Cancer Discov March 1 2013 (3) (3) OF2; DOI: 10.1158/2159-8290.CD-NB2013-016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
India Adds Compulsory Drug Licenses
Cancer Discov March 1 2013 (3) (3) OF2; DOI: 10.1158/2159-8290.CD-NB2013-016
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Proteomics Sharpens Brain Tumor Genomic Analysis
  • Uncovering a Culprit in CAR-T Resistance
  • Artificial Intelligence Predicts Drug Response
Show more News in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement